CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Patient Input and Clinical Experts: Zolgensma

Published on: May 26, 2020
Result type: News

CADTH has received the following notice(s) of pending drug submission(s).

Brand name Zolgensma
Generic name onasemnogene abeparvovec
Manufacturer Novartis Pharmaceuticals Canada Inc.
Indication(s) Spinal muscular atrophy (SMA), pediatrics
Project Number SG0649-000
Call for patient input 2020-05-26
Patient input deadline 2020-07-15
Submit patient input Submit
Register as Clinical Expert Register